Legato Capital Management’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Legato Capital Management's VRDN Position: Q3 2026 in Review
Legato Capital Management opened a new position in Viridian Therapeutics (VRDN) in Q3 2026: 29,450 shares worth $606K. The stake represents 0.05% of the portfolio and ranks #500 among its holdings. This is a return to the name: Legato Capital Management previously reported a position in VRDN as recently as Q1 2026.
Legato Capital Management first reported a position in VRDN in Q3 2025 and has held it in 4 quarters since. The position peaked at $710K in Q4 2025. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Legato Capital Management held 29,450 shares of Viridian Therapeutics worth $606K as of Q3 2026.
- Viridian Therapeutics was a new Legato Capital Management position in Q3 2026.
- Viridian Therapeutics made up 0.05% of Legato Capital Management's portfolio in Q3 2026, its #500 holding.
- Legato Capital Management first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 4 quarters since.
- Legato Capital Management's Viridian Therapeutics position peaked at $710K in Q4 2025.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Legato Capital Management's 13F filing for Q3 2026, filed 10 Nov 2026.